Sorbitol

Movemints, LLC Hits Milestone with 15 Million Mints Shipped Globally

Retrieved on: 
Monday, October 24, 2022
LLC, Dentist, Patient, Edible, Standard of care, Xylitol, Orthodontics, Xerostomia, Amazon (company), Sorbitol, Dentistry

PITTSBURGH, Oct. 24, 2022 /PRNewswire-PRWeb/ --Movemints, LLC Hits Milestone with 15 Million Mints Shipped Globally

Key Points: 
  • Since its launch in 2018, Movemints, LLC has shipped more than 15 million Movemints, which are the first and only concave shaped mints designed and formulated to promote optimal tooth movement during orthodontic therapy, to customers in more than 40 countries.
  • The patented, sugar-free mints are comprised of five ingredients - xylitol, sorbitol, natural spearmint flavoring, natural mint flavoring, and magnesium stearate.
  • "Shipping 15 million mints to customers around the globe is a major milestone for Movemints, LLC and indicates that clear aligner patients globally recognize the benefits of chewing a Movemint," said Dr. Dave, who today serves as the company's Chief Executive Officer.
  • To date, Movemints, LLC has shipped more than 15 million mints to customers in more than 40 countries.

Global Intraocular Lens Market Report to 2031 - Players Include Alcon, Bausch Health, Carl Zeiss Meditech and Hoya - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Health, Optical, Diabetes, Adoption, Porter's five forces analysis, Incidence, Sorbitol, Risk, Prevalence, Congenital cataract, National Eye Institute, National Center for Biotechnology Information, Astigmatism, Growth, Partnership, Myopia, Government, Cataract, Patient, Presbyopia, Johnson & Johnson, Eye, NCBI, Approximation error, Severe cognitive impairment, Benchmarking, US, Diabetic retinopathy, Megasphaera, National Center on Education and the Economy, CAGR, Retail, Telescopic sight, Pharmaceutical industry

The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.

Key Points: 
  • The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.
  • Increase in prevalence of cataract and rise in initiatives taken by government to eliminate avoidable blindness drive the growth of the global intraocular lens market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intraocular lens market analysis from 2021 to 2031 to identify the prevailing intraocular lens market opportunities.
  • The report includes the analysis of the regional as well as global intraocular lens market trends, key players, market segments, application areas, and market growth strategies.

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Retrieved on: 
Monday, September 12, 2022
Safety, Therapy, ISIN, Sorbitol, FDA, ClinicalTrials.gov, Prevalence, Neurodegeneration, Life, Baclofen, Muscle, Muscle atrophy, Treatment, Patient, Wheelchair, Risk, Phase II, PMP22, III, Schwann cell, Walking, Running, CMT, CET, Charcot–Marie–Tooth disease, Regulatory News Service, Naltrexone, HD, Occupational therapy, Marketing, EMA, Disease, Pharmaceutical industry, Security (finance)

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Key Points: 
  • Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the HD tested in the prior Phase III clinical study, the PLEO-CMT trial, and the ongoing open-label extension Phase III study, the PLEOCMT-FU trial.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III trial (PLEO-CMT).
  • An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing.

Y Combinator-backed Kiwi Biosciences Launches Novel Portable Enzymes To Make Food Painless For 15% of the Planet

Retrieved on: 
Wednesday, August 31, 2022
Enzyme, Garlic, Y Combinator, Lactase, Monash University, Mannitol, Harvard Innovation Labs, Alpha-galactosidase, Sorbitol, Harvard University, Medicine, Lactose, Biotechnology, FODMAP, IBS, Fructan, United Kingdom, Sugar, MPH, Gastrointestinal disease, Irritable bowel syndrome

CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.
  • These compounds, called FODMAPs, are particularly problematic for people with Irritable Bowel Syndrome (IBS), which affects 15% of the global population.
  • Backed by Y Combinator , Kiwi Biosciences is a human-centered biotech company creating elegant scientific solutions for extraordinary gut relief.
  • On a mission to make food painless, Kiwi Biosciences is working on a polyol-targeting formulation and advancing novel enzyme technologies to address all FODMAPs.

Two new studies substantiate prune's role in bone health and digestive health

Retrieved on: 
Friday, July 29, 2022
Potassium, University, American Journal, Caffeine, Boron, The American Journal of Clinical Nutrition, Woman, Psyllium, Defecation, M.A, Ageing, California Department of Food and Agriculture, Health, Randomized controlled trial, Nutrient, Diet, Vitamin K, Bone density, Adult, Constipation, Inflammation, JAMA Surgery, Manganese, Sorbitol, Food safety, Bernhard von Langenbeck, Dietary supplement, Silviculture, Viticulture, Agriculture

Now, two new studies add further evidence to confirm the positive role that prunes have on overall health.

Key Points: 
  • Now, two new studies add further evidence to confirm the positive role that prunes have on overall health.
  • The researchers found that total hip bone mineral density decreased in the control group, while the 50g prune group preserved bone mineral density.
  • They also play a role in digestive health, by enhancing the gut microbiome, preventing constipation, and easing laxation.
  • The bone and digestive health benefits of prunes rely on a daily serving of at least 50 grams of prunes, or about five whole prunes.

Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Retrieved on: 
Monday, May 30, 2022
Sorbitol, Charcot–Marie–Tooth disease, Disease, Running, ISIN, Wheelchair, Patient, Walking, ClinicalTrials.gov, PMP22, Treatment, Phase II, Neurodegeneration, Life, Baclofen, Naltrexone, Safety, Occupational therapy, Risk, CMT, CET, Therapy, Muscle atrophy, Regulatory News Service, Prevalence, Schwann cell, Completion, Muscle, Pharmaceutical industry, Security (finance)

Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Key Points: 
  • Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III clinical study, the PLEO-CMT trial, and the ongoing open-label extension Phase III study, the PLEOCMT-FU trial.
  • For more information on the PREMIER trial please refer to the About the PREMIER Trial paragraph below.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III trial (PLEO-CMT).

Azuca Introduces New SUGAR ALTERNATIVES for Fast-Acting Edibles

Retrieved on: 
Tuesday, May 17, 2022
Sorbitol, Xylitol, White cane, Glucose, Freezing, Coffee, VP, Wine, Siraitia grosvenorii, Sugar, Erythritol, Multimedia, View, Cheese, Solution, SKU, Bitter, Beer, Date sugar, Chocolate, Patent, Creativity, Facebook, Ice cream, Marketing, Azuca mine, Powder, Smoking, Coconut, Raw, Titan Mare Explorer, THC, Stevia, LinkedIn, Commonly used gamma-emitting isotopes, Drink, Diabetes, Maple, CEO, Food preservation, Soft drink, Demerara, Instagram

NEW YORK, May 17, 2022 /PRNewswire/ -- Leading edibles ingredient company Azuca today announced new innovations for edibles manufacturers seeking fast-acting infusion formulas: Sugar Alternatives.

Key Points: 
  • NEW YORK, May 17, 2022 /PRNewswire/ -- Leading edibles ingredient company Azuca today announced new innovations for edibles manufacturers seeking fast-acting infusion formulas: Sugar Alternatives.
  • "As an infusion partner, AZUCA empowers manufacturers with chef-ready, infused ingredients that seamlessly integrate into production processes for fast-onset products," said Kim Sanchez Rael, President & CEO, Azuca.
  • Azuca's new sugar alternatives are manufactured and produced using our cost-effective manufacturing solution, which can reduce active ingredient waste by up to 65% compared to traditional edibles manufacturing.
  • The latest sugar alternatives compatible with AZUCA TiME INFUSION include:
    Allulose - A low-calorie sweetener that is found in products such as wheat, jackfruit, figs, and raisins.

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

Retrieved on: 
Monday, May 16, 2022
Sorbitol, Disease, HD, PMP22, Lead, Naltrexone, Standard of care, Risk, High-dose chemotherapy and bone marrow transplant, CMT, Safety, Muscle atrophy, Prevalence, LD, Degenerative disease, Walking, ClinicalTrials.gov, Neurodegeneration, Schwann cell, Charcot–Marie–Tooth disease, Running, Doctor of Philosophy, Patient, Human, Occupational therapy, Therapy, MD, ALS, Data analysis, ISIN, Wheelchair, Phase II, Life, Baclofen, CET, Muscle, Pharmaceutical industry

The entire CMT community is hopeful that PXT3003 could be the first approved therapy for this debilitating disease.

Key Points: 
  • The entire CMT community is hopeful that PXT3003 could be the first approved therapy for this debilitating disease.
  • All randomized CMT1A patients who completed the PLEO-CMT trial (treated with PXT3003 or placebo) were eligible to pursue treatment with PXT3003 in the PLEO-CMT-FU trial.
  • This trial enrolled a total of 187 patients and was designed to primarily assess the long-term safety and tolerability of PXT3003.
  • Patients treated with placebo in the PLEO-CMT trial were randomized in PLEO-CMT-FU to receive LD or HD of PXT3003.

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

Retrieved on: 
Monday, May 16, 2022
Sorbitol, Disease, HD, PMP22, Lead, Naltrexone, Standard of care, Risk, High-dose chemotherapy and bone marrow transplant, CMT, Safety, Muscle atrophy, Prevalence, LD, Degenerative disease, Walking, ClinicalTrials.gov, Neurodegeneration, Schwann cell, Charcot–Marie–Tooth disease, Running, Doctor of Philosophy, Patient, Human, Occupational therapy, Therapy, MD, ALS, Data analysis, ISIN, Wheelchair, Phase II, Life, Baclofen, CET, Muscle, Pharmaceutical industry

The entire CMT community is hopeful that PXT3003 could be the first approved therapy for this debilitating disease.

Key Points: 
  • The entire CMT community is hopeful that PXT3003 could be the first approved therapy for this debilitating disease.
  • All randomized CMT1A patients who completed the PLEO-CMT trial (treated with PXT3003 or placebo) were eligible to pursue treatment with PXT3003 in the PLEO-CMT-FU trial.
  • This trial enrolled a total of 187 patients and was designed to primarily assess the long-term safety and tolerability of PXT3003.
  • Patients treated with placebo in the PLEO-CMT trial were randomized in PLEO-CMT-FU to receive LD or HD of PXT3003.

Applied Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Sorbitol, Phenotype, Galactitol, Company, Disease, American College, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, Nerve, Nasdaq, Doctor of Philosophy, Patient, Investment, PMM2-CDG, Insurance, Ribosomal s6 kinase, Therapy, ARI, Lists of diseases, Eye, Diabetic cardiomyopathy, Trial of the century, FDA, CNS, Intention, Medical genetics, Forward-looking statement, Diabetic retinopathy, Central nervous system, Heart, NDA, Society, Twitter, CEO, GLOBE, Pharmaceutical industry, Cryptocurrency, Galactosemia, Genomics, SORD

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2022.
  • We made significant progress in the first quarter across all three of our Phase 3 programs, said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
  • In January 2022, the Company announced that the FDA would require clinical outcomes data for approval.
  • Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.